Biosimilars Poll: What Should Qualify for Interchangeable Status?

Interchangeable status for biosimilars under current FDA policy allows pharmacists to fill prescriptions with these agents instead of more costly originator drugs, without having to seek approval from a patient’s physician. But interchangeable status requires an additional layer of FDA review and is not automatically granted with FDA approval of each new biosimilar; and no biosimilars, insulin or otherwise, have yet achieved this status.